Dabrafenib in BRAFV600E mutant pilocytic astrocytoma
Sign Up to like & getrecommendations! Published in 2020 at "Child's Nervous System"
DOI: 10.1007/s00381-020-04527-4
Abstract: Dear Editor: We read the report on “Dabrafenib in BRAFV600E mutant pilocytic astrocytoma (PA) in a pediatric patient” with a great interest [1]. Mustansir et al. concluded that “We report a case of successful treatment… read more here.
Keywords: pilocytic astrocytoma; dabrafenib; mutant pilocytic; dabrafenib brafv600e ... See more keywords
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001376
Abstract: Isocitrate dehydrogenase wild-type glioblastoma is the most frequent primary brain tumor in adult patients and its prognosis is still dismal with a median survival of about 1 year. BRAFV600E mutation, an important target for personalized therapy,… read more here.
Keywords: glioblastoma; brafv600e mutant; brafv600e; sox2 amplification ... See more keywords
Effect of cyasterone on intestinal flora in a BRAFV600E-mutant mouse model of colorectal cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Die Pharmazie"
DOI: 10.1691/ph.2022.2422
Abstract: BRAF V600E-mutated colorectal cancer (CRC) is very aggressive and responds poorly to standard treatment. In this study, BRAFV600E-mutant mice with CRC were treated with intragastric cyasterone, a compound commonly used in traditional Chinese herbal medicine,… read more here.
Keywords: effect cyasterone; colorectal cancer; intestinal flora; brafv600e mutant ... See more keywords
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15982
Abstract: Abstract Background/Aim: Metastatic colorectal cancer (mCRC) is a heterogeneous disease with distinct molecular subtypes. The BRAFV600E-mutation found in approximately 8-12% of mCRC patients is associated with poor prognosis. Guideline recommendations for this population are mostly… read more here.
Keywords: metastatic colorectal; treatment; retrospective analysis; brafv600e mutant ... See more keywords
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13225846
Abstract: Simple Summary The BRAFV600E point mutation is the most common driver mutation in papillary thyroid carcinoma (PTC) and is known to be associated with aggressive clinical features. However, the negative prognostic impact of BRAFV600E on… read more here.
Keywords: papillary thyroid; genes encoding; brafv600e mutant; functional groups ... See more keywords
Sesquiterpene Lactone Deoxyelephantopin Isolated from Elephantopus scaber and Its Derivative DETD-35 Suppress BRAFV600E Mutant Melanoma Lung Metastasis in Mice
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22063226
Abstract: Melanoma is a highly metastatic disease with an increasing rate of incidence worldwide. It is treatment refractory and has poor clinical prognosis; therefore, the development of new therapeutic agents for metastatic melanoma are urgently required.… read more here.
Keywords: melanoma; a375lm5if4g luc; det detd; brafv600e mutant ... See more keywords